Lipid clinics are urgently required in the Iranian public health system

International Journal of Preventive Medicine

Volumn 1, Issue 3, 2010, Pages 172-175

  Ghayour Mobarhan, Majid ^a,b   Kazemi Bajestani, Seyyed Mohammad Reza ^c   Ferns, Gordon ^d  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d KEELE UNIVERSITY   (United Kingdom)

Author keywords

Dyslipidemia; Lipid clinics; Secondary prevention

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CONSULTATION; FEMALE; HEALTH CARE FACILITY; HEALTH CARE SYSTEM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IRAN; LIPID ANALYSIS; LIPID CLINIC; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRESCRIPTION; PUBLIC HEALTH SERVICE; RISK ASSESSMENT; RISK MANAGEMENT; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM;

EID: 79952053891     PISSN: 20087802     EISSN: 20088213     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Khashayar P, Mohagheghi A. The correlation between dyslipidemia and coronary artery disease based on angiographic findings in an Iranian population. Acta Medica Indonesiana 2010; 42: 82-5.
2. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005; 365 (9457): 434-41.
3. Durrington P. Dyslipidaemia. Lancet 2003; 362 (9385): 717-31.
4. Singh V, Deedwania P. Expanding roles for atorvastatin. Drugs Today (Barc) 2008; 44(6): 455-71.
5. 4S Group. Scandinavian simvastatin survival study. Lancet 1995; 345: 1274-5.
6. Despres JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B. HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. Atherosclerosis 2000; 153(2): 263-72.
7. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3(2): 213-19.
8. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370(9601): 1781-90.
9. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366(9493): 1267-78.
10. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352(14): 1425-35.
11. Shaffer J, Wexler LF. Reducing low-density lipoprotein cholesterol levels in an ambulatory care system. Results of a multidisciplinary collaborative practice lipid clinic compared with traditional physicianbased care. Arch Intern Med 1995; 155(21): 2330-5.
12. Harris DE, Record NB, Gipson GW, Pearson TA. Lipid lowering in a multidisciplinary clinic compared with primary physician management. Am J Cardiol 1998; 81(7): 929-33.
13. Yates S, Annis L, Pippins J, Walden S. Does a lipid clinic increase compliance with National Cholesterol Education Program Treatment Guidelines? Report of a case-matched controlled study. South Med J 2001; 94(9): 907-9.
14. Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol 2004; 44(9): 1772-9.
15. Olson KL, Rasmussen J, Sandhoff BG, Merenich JA. Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization. Arch Intern Med 2005; 165(1): 49-54.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 1972; 18: 499-502.
17. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002; 105(3): 310-15.
18. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
19. Pearson GJ, Olson KL, Panich NE, Majumdar SR, Tsuyuki RT, Gilchrist DM, et al. Maintenance of improved lipid levels following attendance at a cardiovascular risk reduction clinic: a 10-year experience. Vasc Health Risk Manag 2008; 4(5): 1127-35.
20. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360(9349): 1903-13.
21. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364(9438): 937-52.
22. Neal B, Turnbull F. Effects of different bloodpressure- lowering regimens on major cardiac events. Lancet 2004; 363(9405): 331-2.
23. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366(9493): 1267-78.